



AIDS MALIGNANCY CONSORTIUM (AMC) AMC Operations & Data Management Center (ODMC)
The Emmes Corporation
401 N. Washington Street, Suite 700
Rockville, MD 20850
Phone: 301-251-1161; Fax: 240-238-2842

PRESS RELEASE

AMC FELLOWSHIP PROGRAM

Rockville, Maryland (September 12, 2018): The AIDS Malignancy Consortium (AMC) is pleased to announce the recipients of the 2018 **AMC Fellowship Program**. The fellowship program was established to encourage and foster the development of new and junior clinical investigators at our domestic and international sites to pursue careers in clinical research trials in HIV-associated malignancies within the context of the AMC. These fellowships are designed to allow the fellow to have dedicated time to participate in the scientific and clinical trials aspects of the AMC. The 2018 AMC Fellowship Recipients are:

Domestic

- Alison G. Chang, MD (University of California, Los Angeles, USA)
- Grant Ellsworth, MD (Weill Medical College of Cornell University, USA)
- Kate Westmoreland, MD (University of North Carolina in Chapel Hill, USA)

International

- Lucas Faustine Kiyeeji, MD (Bugando Medical Center, Tanzania)
- Edith Matsikidze, MBChB (University of Zimbabwe, Zimbabwe)

Lab/Translational

- Marta Epeldegui, PhD (University of California, Los Angeles, USA)
- Ryan McNamara, PhD (University of North Carolina in Chapel Hill, USA)

In addition, we congratulate the following second year AMC International and Domestic Fellows who have demonstrated adequate progress and participation in AMC activities during their first-year fellowship:

- Matthew Painschab, MD (University of North Carolina at Chapel Hill, USA)
- Ayana Morales, MD (Weill Medical College of Cornell University, USA)
- Polina Shindiapina, MD, PhD (Ohio State University, USA)
- Simbarashe Chinyowa, MD (University of Zimbabwe, Zimbabwe)
- Carlyn Rose Tan, MD (Fox Chase Cancer Center, USA)

About the AMC

The ***AIDS Malignancy Consortium (AMC)*** develops and conducts innovative trials for HIV-infected patients with AIDS-related cancers. The AMC is a National Cancer Institute-supported clinical trials group founded in 1995 and is composed of 38 clinical trial sites worldwide, five Working Groups, an Administrative Office, a Statistical Office, and an Operations and Data Management Office. Collectively, these components develop and oversee the scientific agenda, manage the groups' portfolio of clinical trials and other scientific-based studies, and help to develop new protocols. The AMC mission is to investigate new treatment and prevention interventions for malignancies in people living with HIV and to study the pathobiology of these tumors in the context of clinical trials. The Working Groups that deal with the cancers that affect HIV-positive patients are Kaposi Sarcoma, Lymphoma, Human Papillomavirus-related Cancers (for example, anal and cervical cancers), and Non-AIDS Defining Cancers (such as, lung cancer, head and neck cancer, liver cancer). The Laboratory Working Group oversees the Central Laboratories of the AMC and develops laboratory studies to answer important scientific questions related to cancer in HIV-positive patients.

For more information about HIV-malignancies, please visit our website:

<http://www.AIDSCancer.org>